Literature DB >> 27170333

Mark-specific additive hazards regression with continuous marks.

Dongxiao Han1, Liuquan Sun2, Yanqing Sun3, Li Qi4.   

Abstract

For survival data, mark variables are only observed at uncensored failure times, and it is of interest to investigate whether there is any relationship between the failure time and the mark variable. The additive hazards model, focusing on hazard differences rather than hazard ratios, has been widely used in practice. In this article, we propose a mark-specific additive hazards model in which both the regression coefficient functions and the baseline hazard function depend nonparametrically on a continuous mark. An estimating equation approach is developed to estimate the regression functions, and the asymptotic properties of the resulting estimators are established. In addition, some formal hypothesis tests are constructed for various hypotheses concerning the mark-specific treatment effects. The finite sample behavior of the proposed estimators is evaluated through simulation studies, and an application to a data set from the first HIV vaccine efficacy trial is provided.

Entities:  

Keywords:  Additive hazards model; Competing risks; Confidence bands and tests; Continuous mark; HIV vaccine trial; Mark-specific vaccine effects; Survival data

Mesh:

Substances:

Year:  2016        PMID: 27170333      PMCID: PMC5319915          DOI: 10.1007/s10985-016-9369-9

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  11 in total

1.  Tests for comparing mark-specific hazards and cumulative incidence functions.

Authors:  Peter B Gilbert; Ian W McKeague; Yanqing Sun
Journal:  Lifetime Data Anal       Date:  2004-03       Impact factor: 1.588

2.  The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.

Authors:  Peter B Gilbert; Ian W McKeague; Yanqing Sun
Journal:  Biostatistics       Date:  2007-08-17       Impact factor: 5.899

3.  Simple parametric and nonparametric models for excess and relative mortality.

Authors:  P K Andersen; M Vaeth
Journal:  Biometrics       Date:  1989-06       Impact factor: 2.571

4.  Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark.

Authors:  Yanqing Sun; Mei Li; Peter B Gilbert
Journal:  Comput Stat Data Anal       Date:  2014-12-03       Impact factor: 1.681

5.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

6.  Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.

Authors:  Yanqing Sun; Mei Li; Peter B Gilbert
Journal:  Biostatistics       Date:  2012-07-03       Impact factor: 5.899

7.  PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.

Authors:  Yanqing Sun; Peter B Gilbert; Ian W McKeague
Journal:  Ann Stat       Date:  2009-02-01       Impact factor: 4.028

8.  Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials.

Authors:  Peter B Gilbert; Yanqing Sun
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2015-01-01       Impact factor: 1.864

9.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

10.  Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks.

Authors:  Yanqing Sun; Peter B Gilbert
Journal:  Scand Stat Theory Appl       Date:  2012-03       Impact factor: 1.396

View more
  1 in total

1.  Variable selection for a mark-specific additive hazards model using the adaptive LASSO.

Authors:  Dongxiao Han; Lianqiang Qu; Liuquan Sun; Yanqing Sun
Journal:  Stat Methods Med Res       Date:  2021-07-15       Impact factor: 2.494

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.